Atyr PHARMA INC (NASDAQ:ATYR) Receives $18.60 Consensus PT from Brokerages

Atyr PHARMA INC (NASDAQ:ATYR) has earned a consensus rating of “Buy” from the seven analysts that are presently covering the company, Marketbeat reports. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $18.60.

Several research firms have recently weighed in on ATYR. Leerink Partnrs raised shares of Atyr PHARMA to a “strong-buy” rating in a research report on Tuesday, February 18th. Cantor Fitzgerald began coverage on Atyr PHARMA in a report on Monday, January 6th. They issued an “overweight” rating for the company. HC Wainwright reaffirmed a “buy” rating and set a $35.00 target price on shares of Atyr PHARMA in a report on Friday. Finally, Leerink Partners began coverage on Atyr PHARMA in a report on Tuesday, February 18th. They issued an “outperform” rating and a $16.00 price target for the company.

Hedge Funds Weigh In On Atyr PHARMA

Large investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. boosted its stake in Atyr PHARMA by 52.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 31,440 shares of the company’s stock valued at $55,000 after purchasing an additional 10,754 shares in the last quarter. Kingswood Wealth Advisors LLC acquired a new stake in shares of Atyr PHARMA in the fourth quarter valued at $170,000. Alterna Wealth Management Inc. bought a new position in Atyr PHARMA during the fourth quarter valued at about $36,000. D.A. Davidson & CO. acquired a new position in Atyr PHARMA during the fourth quarter worth about $141,000. Finally, Charles Schwab Investment Management Inc. bought a new stake in Atyr PHARMA in the fourth quarter worth about $144,000. Institutional investors and hedge funds own 61.72% of the company’s stock.

Atyr PHARMA Price Performance

Shares of NASDAQ ATYR opened at $4.01 on Friday. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.41 and a quick ratio of 5.41. Atyr PHARMA has a 1-year low of $1.42 and a 1-year high of $4.66. The company has a market capitalization of $336.61 million, a price-to-earnings ratio of -4.27 and a beta of 0.98. The business has a 50-day moving average of $3.65 and a 200-day moving average of $3.09.

Atyr PHARMA (NASDAQ:ATYR) last released its quarterly earnings results on Thursday, March 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.05. On average, equities analysts anticipate that Atyr PHARMA will post -0.91 EPS for the current fiscal year.

About Atyr PHARMA

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.